Novo Nordisk A/S is turning to Germany’s Evotec SE to help the Danish diabetes and obesity specialist use its reservoir of patient information, as well as other data sources, to identify, develop and commercialize novel therapies for treating chronic kidney disease (CKD).
The two companies on 18 August said they would jointly identify and develop new targets based on comprehensive medical and...








